Ariad Pharmaceuticals Inc. agreed to pay mid-single-digit royalties on futures sales of Iclusig (ponatinib) to PDL Biopharma Inc. in exchange for up to $200 million in financing intended to accelerate testing of brigatinib, an anaplastic lymphoma kinase (ALK) inhibitor it is developing to treat non-small-cell lung cancer (NSCLC), and to continue its ongoing initiatives supporting both drugs.